2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase
  5. CA XIII Isoform

CA XIII

CA XIII is a cytosolic carbonic anhydrase isozyme that catalyzes CO2 hydration and is expressed in several normal tissues[1]. Mechanistically, recombinant mouse CA XIII showed catalytic activity similar to mitochondrial CA V and cytosolic CA I, supporting its role in physiological acid-base processes[1]. In colorectal mucosa, CA XIII expression is down-regulated in tumor cells compared with normal tissue, and the lowest signal was detected in carcinoma samples[2]. Compared with related cytosolic isoforms, CA XIII showed a unique and widespread distribution pattern distinct from CA I, CA II, and CA III[1]. Structurally, human CA XIII has high similarity to cytosolic isozymes but active-site differences support isozyme-specific inhibitor design[3]. For experimental applications, CA XIII is efficiently inhibited by sulfonamide inhibitors, including acetazolamide, while intrinsic thermodynamic studies support structure-activity analysis of CA XIII inhibitor binding[1][4].

CA XIII Related Products (2):

Cat. No. Product Name Effect Purity
  • HY-109056
    Elsulfavirine
    		Inhibitor 99.90%
    Elsulfavirine (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine is used in studies related to HIV-1 infection and liver cancer.
  • HY-109056A
    Elsulfavirine sodium
    		Inhibitor
    Elsulfavirine sodium (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine sodium also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine sodium and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine sodium is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine sodium exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine sodium is used in studies related to HIV-1 infection and liver cancer.